Clinical Trials Logo

Glioma clinical trials

View clinical trials related to Glioma.

Filter by:

NCT ID: NCT03990597 Withdrawn - Glioma Clinical Trials

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

Start date: August 19, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of a silicone topical wound dressing (StrataXRT) and to see how well it works in preventing radiation dermatitis (skin burns and side effects caused by radiation) in pediatric patients undergoing radiation therapy. StrataXRT may help prevent or decrease severe skin rash, pain, itching, skin peeling, and dry skin in pediatric patients undergoing radiation therapy to the brain or spinal cord.

NCT ID: NCT03973879 Withdrawn - Malignant Glioma Clinical Trials

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Start date: February 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the safety of PVSRIPO treatment in combination with Atezolizumab in patients with WHO grade IV malignant glioma. All patients will receive a single PVSRIPO infusion followed by atezolizumab infusions every three weeks for up to two years.

NCT ID: NCT03956706 Withdrawn - Glioblastoma Clinical Trials

Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas

Start date: December 24, 2018
Phase: N/A
Study type: Interventional

Several investigations suggest neural stem cells located in the subventricular region play an active role in promoting or even initiating cortical malignant glioma growth. Although normal appearing on neuroimaging, surgical specimens taken from this region show it contains malignant glioma stem-like cells. Some retrospective analyses found patients who received radiation therapy to this region during standard of care treatments lived longer than patients who did not. The investigator's study hypothesizes (1) stereotactic radiosurgery of cancer stem-like cells in these regions will be well tolerated during standard of care therapy, (2) focused stereotactic radiosurgery will be more effective in destroying cancer stem cells than conventional radiation therapy, and (3) treatment will improve malignant glioma survival.

NCT ID: NCT03935269 Withdrawn - Glioma Clinical Trials

Cereset for Caregivers

CERESET
Start date: March 2024
Phase: N/A
Study type: Interventional

In this single arm, open label study, investigators will evaluate the feasibility of using the Cereset (formerly known as HIRREM - high-resolution relational, resonance-based electroencephalic mirroring) intervention for a stressed population confronting an acute burden on their lives - caregivers of newly diagnosed high-grade glioma patients. The Cereset intervention is a closed-loop acoustic stimulation intervention that has been studied in patients with PTSD, insomnia, postural orthostatic tachycardia, and military veterans.

NCT ID: NCT03796507 Withdrawn - Glioma of Brain Clinical Trials

Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation

Start date: September 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to investigate the feasibility of a possible treatment regimen that could be used to delay tumor progression in patients with glioblastoma. The study is being conducted in patients who qualify for inpatient rehabilitation, as this population is particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in the period between surgical resection and the start of treatment.

NCT ID: NCT03649464 Withdrawn - Glioblastoma Clinical Trials

Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants

Start date: August 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to investigate tolerability, safety, pharmacokinetics (PK) and efficacy of oral OKN-007 in participants with recurrent high-grade glioma.

NCT ID: NCT03632317 Withdrawn - Glioma Clinical Trials

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Start date: October 2019
Phase: Phase 2
Study type: Interventional

This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

NCT ID: NCT03275558 Withdrawn - Clinical trials for Recurrent Glioblastoma

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Start date: July 17, 2018
Phase: Phase 1
Study type: Interventional

This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma, Gliosarcoma,Anaplastic Gliomas, Previously Treated). All drugs target the inhibition of the growth factors and neo-angiogenesis as one the main reasons for the growth of the tumor. The purpose of the Nasal Spray NST-4G study is to determine the safety and tolerability in order to establish the best dose level to be used in future studies.

NCT ID: NCT03252171 Withdrawn - Clinical trials for CAR-T Cell Immunotherapy

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Start date: October 15, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

NCT ID: NCT03193463 Withdrawn - Glioma Clinical Trials

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

Start date: November 3, 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan into your brain tumor. A second purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan into your brain tumor. This study will also determine the best dose of topotecan to deliver to your tumor with use of the Cleveland Multiport Catheter and will also examine how your tumor responds to treatment with topotecan.